Home > Insider Trading > Filing (0001179110-14-008277)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1065087	Albany Molecular Research Inc	AMRI	Services-Commercial Physical & Biological Research (8731)	141742717

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1449207	R Steven Hagen	26 Corporate Circle Albany NY 12203	Svp Pharmaceutical Dev & Mfg	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2014-05-09	897	$14.80	33,433	No	4	S	Direct
Common Stock	Acquisiton	2014-05-09	2,500	$2.93	35,933	No	4	M	Direct
Common Stock	Disposition	2014-05-09	2,500	$14.80	33,433	No	4	S	Direct
Common Stock	Acquisiton	2014-05-12	2,500	$2.93	35,933	No	4	M	Direct
Common Stock	Disposition	2014-05-12	2,500	$15.27	33,433	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Option to purchase Common Stock	Disposition	2014-05-09	2,500	$2.93	2,500	$2.93
Common Stock	Option to purchase Common Stock	Disposition	2014-05-12	2,500	$2.93	2,500	$2.93

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
22,500		2022-02-17	No	4	M	Direct
20,000		2022-02-17	No	4	M	Direct

Footnotes

50% of grant is time based and 50% is performance based. Time based grant vests 25% per year on each of the first 4 anniversaries of the date of grant (February 17, 2012). Performance based grant vests 25% per year on each of the first 4 anniversaries of the grant date if (1) certain performance criteria related to the Company's operating profitability are reached and (2) the grantee is employed on such anniversary date; if the foregoing criteria are not met on any anniversary date, 25% of the shares of options under the performance award will immediately be forfeited. The 2,500 shares being exercised represent a portion of the vested grants. 50% of the intial grant is not yet exercisable.